Regeneron Pharmaceuticals Inc. said on November 8 a single dose of the company’s antibody cocktail reduced the risk of contracting Covid-19 by 81.6 percent in a late-stage trial, in the two to eight months period following the drug’s administration.
Researchers with the University of Cambridge for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
British scientists identified a version of a gene that may be associated with double the risk of lung failure from Covid-19, a finding that provides new insights into why some people are more susceptible than others to severe illness and which opens possibilities for targeted medicine.
GlaxoSmithKline said the company’s anemia pill for patients with kidney disease was shown to have about the same side effect risk as the current standard treatment in two important patient groups, a key advantage in a tight race with rival drug developers.
Pfizer plans to seek Emergency Use Authorization (EUA) for an antiviral Covid-19 treatment following an interim analysis of Phase II/III data shown to be statistically and clinically meaningful.
Ocugen Inc. announced Nov. 5 that the biopharmaceutical company submitted a request to the U.S. Food and Drug Administration for Emergency Use Authorization (EUA) of the Covid-19 vaccine candidate BBV152, known as Covaxin outside of the United States, for pediatric use.
Vaccine developer Novavax Inc. said on Nov. 4 that the company completed the submission process for emergency use listing of the Covid-19 vaccine candidate NVX-CoV2373 with the World Health Organization.
Researchers in Singapore developed the world’s largest and highest-resolution atlas of gastric cancer.
Several studies point to promising new approaches to treating and preventing Alzheimer’s disease and a deeper understanding of how the disease progresses.
People can get inoculated against Covid-19 and the seasonal influenza at the same time without compromising the vaccines’ effectiveness, a World Health Organization official said on November 4.
